Lyka Labs Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Lyka Labs Ltd is ₹ 60.49 as of 30 Apr 15:30 . The P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 45.1 on March 2025 . This represents a CAGR of 45.73% over 4 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Lyka Labs Ltd changed from ₹ 74.59 crore on March 2021 to ₹ 360.29 crore on March 2025 . This represents a CAGR of 37.02% over 5 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Lyka Labs Ltd for the Dec '25 is ₹ 31.89 crore as compare to the Sep '25 revenue of ₹ 37.75 crore. This represent the decline of -15.52% The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Sep '25 revenue of ₹ 167.17 crore. This represent the growth of 6.68% The ebitda of Lyka Labs Ltd for the Dec '25 is ₹ 2.81 crore as compare to the Sep '25 ebitda of ₹ -1.45 crore. This represent the decline of -293% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Sep '25 ebitda of ₹ 54.92 crore. This represent the growth of 5.23% The net profit of Lyka Labs Ltd changed from ₹ 1.29 crore to ₹ -0.15 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Lyka Labs Ltd

Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
It also added a range of ayurvedic and animal health care products over the years.
In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
Lyka Exports is the subsidiary of the company.
The Company is engaged in the development, manufacture and marketing of quality finished dosages. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Lyka Labs Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Lyka Labs Ltd or Senores Pharmaceuticals Ltd?

Market cap of Lyka Labs Ltd is 215 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,138 Cr

What are the key factors driving the stock performance of Lyka Labs Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Lyka Labs Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lyka Labs Ltd and Senores Pharmaceuticals Ltd?

As of May 3, 2026, the Lyka Labs Ltd stock price is INR ₹60.49. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹898.7.

How do dividend payouts of Lyka Labs Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lyka Labs Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.